BRCA1-话题@MedSci

#BRCA1#

54篇内容 | 2546人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1423318, encodeId=adfc142331865, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=J Clin Oncol：注意！携带BRCA1致病性突变的女性或卵巢储备功能下降！, objectType=article, longId=210532, objectId=94d6210532be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94d6210532be, replyNumber=0, likeNumber=125, createdTime=2021-04-28, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94d6210532be, moduleTitle=J Clin Oncol：注意！携带BRCA1致病性突变的女性或卵巢储备功能下降！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94d6210532be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423317, encodeId=0252142331e3f, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果 , objectType=article, longId=209040, objectId=19e420904055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19e420904055, replyNumber=0, likeNumber=141, createdTime=2021-03-28, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19e420904055, moduleTitle=Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19e420904055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423316, encodeId=7dbb1423316b2, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Nat Commun：BRCA1/BRCA2突变携带者的乳腺癌发病风险研究, objectType=article, longId=207488, objectId=3be820e4881c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3be820e4881c, replyNumber=0, likeNumber=129, createdTime=2021-02-24, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3be820e4881c, moduleTitle=Nat Commun：BRCA1/BRCA2突变携带者的乳腺癌发病风险研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3be820e4881c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423315, encodeId=598d14233152a, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS, objectType=article, longId=206058, objectId=87ad20605893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87ad20605893, replyNumber=0, likeNumber=90, createdTime=2021-01-24, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87ad20605893, moduleTitle=BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87ad20605893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423314, encodeId=a6271423314c7, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响, objectType=article, longId=205690, objectId=826020569015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=826020569015, replyNumber=0, likeNumber=94, createdTime=2021-01-14, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=826020569015, moduleTitle=Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=826020569015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423313, encodeId=a881142331300, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=ESMO Open：致病性BRCA1/2胚系突变在胰腺癌患者中的发生率, objectType=article, longId=205519, objectId=bf4a2055190b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf4a2055190b, replyNumber=0, likeNumber=88, createdTime=2021-01-10, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf4a2055190b, moduleTitle=ESMO Open：致病性BRCA1/2胚系突变在胰腺癌患者中的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf4a2055190b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423312, encodeId=3500142331203, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Brit J Surg：BRCA1和/或BRCA2突变携带者大肠癌风险, objectType=article, longId=192509, objectId=e7681925097d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7681925097d, replyNumber=0, likeNumber=0, createdTime=2020-04-20, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7681925097d, moduleTitle=Brit J Surg：BRCA1和/或BRCA2突变携带者大肠癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7681925097d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423311, encodeId=e56114233118a, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者, objectType=article, longId=186454, objectId=6fbf186454dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fbf186454dd, replyNumber=0, likeNumber=80, createdTime=2020-01-19, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fbf186454dd, moduleTitle=英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fbf186454dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423310, encodeId=8c2e14233101e, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Eur Urol：男性BRCA1和BRCA2变异位点携带者前列腺癌风险研究, objectType=article, longId=180269, objectId=8b7c18026916, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b7c18026916, replyNumber=0, likeNumber=73, createdTime=2019-10-01, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b7c18026916, moduleTitle=Eur Urol：男性BRCA1和BRCA2变异位点携带者前列腺癌风险研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b7c18026916)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423309, encodeId=32d61423309b7, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Lancet Oncol：宫颈阴道微生物群、BRCA1突变状态和卵巢癌发病风险, objectType=article, longId=175435, objectId=1b8c1e543544, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b8c1e543544, replyNumber=0, likeNumber=80, createdTime=2019-07-16, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b8c1e543544, moduleTitle=Lancet Oncol：宫颈阴道微生物群、BRCA1突变状态和卵巢癌发病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b8c1e543544)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423308, encodeId=61b714233083f, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=MOL CELL：什么是BRCA1 / 2缺失的乳腺癌细胞存活必须的?, objectType=article, longId=174769, objectId=f4711e4769b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4711e4769b7, replyNumber=0, likeNumber=58, createdTime=2019-07-05, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4711e4769b7, moduleTitle=MOL CELL：什么是BRCA1 / 2缺失的乳腺癌细胞存活必须的?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4711e4769b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423307, encodeId=be0f142330e11, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Brit J Cancer：高度和体重指数与BRCA1和BRCA2突变携带者卵巢癌风险, objectType=article, longId=169031, objectId=f0df169031d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0df169031d5, replyNumber=0, likeNumber=69, createdTime=2019-06-25, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0df169031d5, moduleTitle=Brit J Cancer：高度和体重指数与BRCA1和BRCA2突变携带者卵巢癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0df169031d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423306, encodeId=369214233064d, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Nature：BRCA1突变真是乳腺和卵巢的“致癌炸弹”吗？科学家利用CRISPR终于揭开了数千种变异的意义, objectType=article, longId=151484, objectId=538015148427, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=538015148427, replyNumber=0, likeNumber=60, createdTime=2018-10-22, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=538015148427, moduleTitle=Nature：BRCA1突变真是乳腺和卵巢的“致癌炸弹”吗？科学家利用CRISPR终于揭开了数千种变异的意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=538015148427)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423305, encodeId=2f5414233056d, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Brit J Cancer：IVF卵巢刺激与BRCA1/2突变携带者原发性乳腺癌风险！, objectType=article, longId=141707, objectId=f022141e0757, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f022141e0757, replyNumber=0, likeNumber=59, createdTime=2018-06-28, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f022141e0757, moduleTitle=Brit J Cancer：IVF卵巢刺激与BRCA1/2突变携带者原发性乳腺癌风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f022141e0757)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423304, encodeId=49a7142330434, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究, objectType=article, longId=137196, objectId=7db713e1967a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7db713e1967a, replyNumber=0, likeNumber=87, createdTime=2018-05-05, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7db713e1967a, moduleTitle=Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7db713e1967a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423303, encodeId=d61b142330386, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Ann Intern Med：白细胞BRCA1启动子甲基化状态与卵巢癌风险！, objectType=article, longId=134108, objectId=35eb134108f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35eb134108f7, replyNumber=0, likeNumber=85, createdTime=2018-04-04, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35eb134108f7, moduleTitle=Ann Intern Med：白细胞BRCA1启动子甲基化状态与卵巢癌风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35eb134108f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423302, encodeId=432f1423302d1, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=ANN ONCOL：局部复发或转移性BRCA1/2乳腺癌患者治疗方案比较, objectType=article, longId=127478, objectId=90d712e4782d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90d712e4782d, replyNumber=0, likeNumber=77, createdTime=2018-01-25, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90d712e4782d, moduleTitle=ANN ONCOL：局部复发或转移性BRCA1/2乳腺癌患者治疗方案比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90d712e4782d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423301, encodeId=566f142330133, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Ann Intern Med：白细胞BRCA1启动子甲基化状态与卵巢癌发生风险之间的关系, objectType=article, longId=127217, objectId=36f312e21700, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36f312e21700, replyNumber=0, likeNumber=81, createdTime=2018-01-23, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36f312e21700, moduleTitle=Ann Intern Med：白细胞BRCA1启动子甲基化状态与卵巢癌发生风险之间的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36f312e21700)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423300, encodeId=2d811423300ac, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗, objectType=article, longId=106877, objectId=eba21068e7a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba21068e7a6, replyNumber=0, likeNumber=70, createdTime=2017-07-28, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba21068e7a6, moduleTitle=Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba21068e7a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423299, encodeId=0959142329952, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, objectTitle=除BRCA1和BRCA2外，乳腺癌遗传易感性还与哪些突变相关？, objectType=article, longId=106502, objectId=594610650285, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=594610650285, replyNumber=0, likeNumber=0, createdTime=2017-07-26, rootId=0, userName=caobinglei8080, userId=7a3d3767712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=594610650285, moduleTitle=除BRCA1和BRCA2外，乳腺癌遗传易感性还与哪些突变相关？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=594610650285)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BRCA1

2020-05-29

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

J Clin Oncol：注意！携带BRCA1致病性突变的女性或卵巢储备功能下降！

2021-04-28

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果

2021-03-28

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Nat Commun：BRCA1/BRCA2突变携带者的乳腺癌发病风险研究

2021-02-24

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS

2021-01-24

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响

2021-01-14

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

ESMO Open：致病性BRCA1/2胚系突变在胰腺癌患者中的发生率

2021-01-10

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Brit J Surg：BRCA1和/或BRCA2突变携带者大肠癌风险

2020-04-20

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者

2020-01-19

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Eur Urol：男性BRCA1和BRCA2变异位点携带者前列腺癌风险研究

2019-10-01

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Lancet Oncol：宫颈阴道微生物群、BRCA1突变状态和卵巢癌发病风险

2019-07-16

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

MOL CELL：什么是BRCA1 / 2缺失的乳腺癌细胞存活必须的?

2019-07-05

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Brit J Cancer：高度和体重指数与BRCA1和BRCA2突变携带者卵巢癌风险

2019-06-25

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Nature：BRCA1突变真是乳腺和卵巢的“致癌炸弹”吗？科学家利用CRISPR终于揭开了数千种变异的意义

2018-10-22

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Brit J Cancer：IVF卵巢刺激与BRCA1/2突变携带者原发性乳腺癌风险！

2018-06-28

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究

2018-05-05

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Ann Intern Med：白细胞BRCA1启动子甲基化状态与卵巢癌风险！

2018-04-04

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

ANN ONCOL：局部复发或转移性BRCA1/2乳腺癌患者治疗方案比较

2018-01-25

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Ann Intern Med：白细胞BRCA1启动子甲基化状态与卵巢癌发生风险之间的关系

2018-01-23

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗

2017-07-28

caobinglei8080 (审核中...)

前往app查看评论内容

#BRCA1#

除BRCA1和BRCA2外，乳腺癌遗传易感性还与哪些突变相关？

2017-07-26

科室
- - 订阅+
  - 更多科室
工具
服务